Probi agreement enhanced to strengthen alliance
BLIS Technologies Limited
399 Moray Place, Dunedin, New Zealand, 9016
blis.co.nz
info@blis.co.nz
28 October 2025
Probi agreement enhanced to strengthen alliance
BLIS Technologies Limited (NZX: BLT) has signed an agreement with Probi AB (Probi) to enhance their
collaborative efforts in the global probiotic market. This agreement extends the existing Technology
License & Distribution Agreement and provides Probi exclusive rights to BLIS K12® and BLIS M18®
across the USA, Canada, and certain EMEA markets.
For the first time, this agreement introduces pet nutrition into Probi's licensed territories, tapping
into the burgeoning pet health market and responding to increasing consumer demand for high-
quality probiotic solutions for pets.
“We are excited to deepen our partnership with Probi,” said Scott Johnson, CEO. “This agreement
not only strengthens our foothold in human wellbeing but also aligns with the growing opportunity
to provide innovative solutions in pet health.”
This collaboration underscores our shared vision to lead in the rapidly expanding probiotic market
and deliver exceptional value to our customers and stakeholders.
Ends
For further information, please contact:
Scott Johnson
Chief Executive Officer
+64 21 488 831
About BLIS Technologies Ltd
Delivering proven health benefits through evidence-based, advanced probiotics
BLIS Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut.
Combining innovation with evidence-based research and the highest quality production controls enables
the delivery of probiotic solutions for specific health targets including ears, nose, and throat health, halitosis
(bad breath), immune support, teeth and gum health and skin health. BLIS
®
products are sold throughout
New Zealand and in Asia, Europe and the USA. More information about BLIS Technologies Ltd can be found
at www.blis.co.nz.
Website: www.blis.co.nz
Instagram: @blisprobiotics #blisk12 #blism18
Facebook: @BLISProbiotics
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- CVT — Comvita Limited: Comvita Scheme Booklet and Notice of Meeting2025-10-14
“53 § BLIS is a small NZX listed company that develops and sells healthcare products based on strains of bacteria. The company offers BLIS K12 (an oral probiotic supplement to support ear, nose and throat health as well as for enhancing immunity and bad breath), BLIS M18 (…”
- BIF — Booster Innovation Fund: BIF adds Cadmus Animal Health to its investment portfolio2025-08-06
“Page 1 of 1 6 August 2025 Booster Innovation Fund adds Cadmus Animal Health to its investment portfolio Booster is pleased to announce the addition of Cadmus Animal Health to the Booster Innovation Fund (BIF) portfolio. Cadmus Animal Health operates in the animal…”
- BIF — Booster Innovation Fund: BIF – Partnership Announcement for Booster Innovation Fund2025-12-08
“BIF – Partnership Announcement for Booster Innovation Fund 8 December 2025 NZX Announcement: Booster Innovation Fund – Partnership Expansion with Leading New Zealand Universities Booster Innovation Fund (BIF) is pleased to provide an update on the continued growth of it…”